Please assess the completion status of the following clinical trial:

Trial Title: Pembrolizumab + Idelalisib for Lung Cancer Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
All subjects must have documented metastatic or recurrent NSCLC from biopsy. They must have failed or progressed on platinum-based chemotherapy (e.g. cisplatin, carboplatin) as well as immune checkpoint inhibitor therapy (e.g nivolumab or pembrolizumab). Patients with EGFR/ALK mutations/translocations must have failed or progressed on small molecule inhibitor therapies (e.g. erlotinib, afatinib, etc.).~Inclusion Criteria:~* Have at least one measurable lesion~* Have an ECOG Performance Status of 1 or less~* Demonstrate adequate organ function as defined in the protocol.~* Female subjects of childbearing potential must have a negative pregnancy test before starting treatment; they must also be willing to use two methods of birth control or abstain from heterosexual activity for the duration of the study.~* Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through the duration of the study.~Exclusion Criteria:~* Is currently receiving study drug in another trial; or has participated in an investigational drug study within 3 weeks of the first dose of treatment.~* Is within 3 weeks of most recent chemotherapy.~* Has a history of hypersensitivity to pembrolizumab or idelalisib, or any of their excipients.~* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated, stable, brain metastases may participate; carcinomatous meningitis is excluded regardless of clinical stability.~* Has known history of non-infectious pneumonitis that required steroid use or has current pneumonitis.~* Has a known history of active TB (Bacillus Tuberculosis)~* Has active autoimmune disease that has required treatment; known history of Human Immunodeficiency Virus (HIV); known active Hepatitis B or Hepatitis C.~* Has an active infection requiring systemic therapy.~* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 Dose Escalation (Type: EXPERIMENTAL): Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
- Phase 2 Efficacy (Type: EXPERIMENTAL): All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).